AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 427822 — intervention group
Group type: COMPARATOR
Intervention: oral L‐PAM
Number of subjects: 425
Study 427822 — intervention group
Group type: EXPERIMENTAL
Intervention: oral L‐PAM after iv L‐PAM
Number of subjects: 425
Study 31490342 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178
Study 31490342 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-driven regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178
Study 31490342 — intervention group
Group type: COMPARATOR
Intervention: Event-driven regimen of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Number of subjects: 178
Study 31490342 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting stimulant use
Number of subjects: 178
Study 31490342 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting other nonalcohol drug use
Number of subjects: 178
Study 31490342 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting no substance use
Number of subjects: 178
Study 29244042 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention (patient education and individualized nursing support during a 6-month rehabilitation period)
Number of subjects: 36
Study 29244042 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 36
Study 26044145 — intervention group
Group type: EXPERIMENTAL
Intervention: Caraway oil poultices (CarO)
Number of subjects: 48
Study 26044145 — intervention group
Group type: COMPARATOR
Intervention: Hot olive oil poultice (OlivH)
Number of subjects: 48
Study 26044145 — intervention group
Group type: COMPARATOR
Intervention: Nonheated olive oil poultice (OlivC)
Number of subjects: 48
Study 23821401 — intervention group
Group type: COMPARATOR
Intervention: Flow-mediated dilatation (FMD) measurements
Number of subjects: 67
Study 21685654 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally charged verbal exchange first (followed by a more neutral verbal exchange)
Number of subjects: 0
Study 21685654 — intervention group
Group type: COMPARATOR
Intervention: Emotionally neutral verbal exchange first (followed by an emotionally charged verbal exchange)
Number of subjects: 0
Study 19543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking intervention after outpatient cardiac rehabilitation for 12 weeks
Number of subjects: 153
Study 19543092 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 153
Study 19543092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking intervention
Number of subjects: 153
Study 17181383 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 100-800 microg
Number of subjects: 0
Study 15516774 — intervention group
Group type: EXPERIMENTAL
Intervention: TabAll tableting process analyzer
Number of subjects: 0
Study 11027754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐incision endoscopic technique
Number of subjects: 20
Study 11027754 — intervention group
Group type: COMPARATOR
Intervention: 2‐incision technique
Number of subjects: 20
Study 8930858 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS consultation
Number of subjects: 16
Study 1841788 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg/daily
Number of subjects: 2356
Study 1841788 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg/daily
Number of subjects: 2356
Study 1841788 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg/daily combined with indobufen 400 mg/daily
Number of subjects: 2356
Study 1841788 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/daily
Number of subjects: 2356
Study 1841788 — intervention group
Group type: EXPERIMENTAL
Intervention: low saturated fat and low cholesterol diet
Number of subjects: 2356
Study 1841788 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with bezafibrate)
Number of subjects: 2356
Study 6195483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol 200 mg once daily
Number of subjects: 19
Study 6195483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol 400 mg once daily
Number of subjects: 19
Study 6195483 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol 400 mg twice daily
Number of subjects: 19
Study 6195483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30654780 — intervention group
Group type: EXPERIMENTAL
Intervention: LHW-delivered care
Number of subjects: 0
Study 30654780 — intervention group
Group type: COMPARATOR
Intervention: Outpatient facility-based care
Number of subjects: 0
Study 28538088 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 28538088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25239172 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine
Number of subjects: 45
Study 25239172 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of saline water (placebo)
Number of subjects: 45
Study 25355252 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Perconditioning (RIPerC)
Number of subjects: 46
Study 25355252 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Postconditioning (RIPostC)
Number of subjects: 46
Study 25355252 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 46
Study 22206591 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence therapy combined with health education for 6 weeks
Number of subjects: 125
Study 22206591 — intervention group
Group type: COMPARATOR
Intervention: Health education only
Number of subjects: 125
Study 20593353 — intervention group
Group type: EXPERIMENTAL
Intervention: Group J (Maquet Quardox)
Number of subjects: 40
Study 20593353 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Affinity NT)
Number of subjects: 40
Study 20593353 — intervention group
Group type: COMPARATOR
Intervention: Group P (Polystan Safe Maxi)
Number of subjects: 40
Study 20593353 — intervention group
Group type: COMPARATOR
Intervention: Group T (Terumo Capiox SX 18)
Number of subjects: 40
Study 20593353 — intervention group
Group type: COMPARATOR
Intervention: Group C (COBE APEX‐TM)
Number of subjects: 40
Study 18838662 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cognitive failures (SCF)
Number of subjects: 503
Study 18838662 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective memory failures (SMF)
Number of subjects: 503
Study 18838662 — intervention group
Group type: EXPERIMENTAL
Intervention: Good objective cognitive performance
Number of subjects: 503
Study 18838662 — intervention group
Group type: COMPARATOR
Intervention: Poor objective cognitive performance
Number of subjects: 503
Study 16037145 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 microg x kg(‐1) x min(‐1) plus 10 microg demands
Number of subjects: 200
Study 16037145 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 0.1 microg x kg(‐1) x min(‐1) plus 10 microg demands
Number of subjects: 200
Study 11981083 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg bolus and 0.25 mg/kg/h continuous infusion for up to 96 h)
Number of subjects: 56
Study 11981083 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 56
Study 10619543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (8-week program including progressive muscle relaxation, guided imagery, self-instruction training, study and test-taking skills)
Number of subjects: 27
Study 10619543 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated, N = 16)
Number of subjects: 27
Study 7552768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.05 mg/kg)
Number of subjects: 17
Study 7552768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2191991 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filter
Number of subjects: 32
Study 2191991 — intervention group
Group type: COMPARATOR
Intervention: Blank filter (Control)
Number of subjects: 32
Study 2191991 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filter (active)
Number of subjects: 32
Study 175726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral adrenergic substances (e.g., ephedrine)
Number of subjects: 0
Study 175726 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors (e.g., theophylline)
Number of subjects: 0
Study 175726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosage combination of oral adrenergic drugs and xanthines
Number of subjects: 0
Study 31086347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab without induction
Number of subjects: 67
Study 31086347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with cisplatin induction
Number of subjects: 67
Study 31086347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with doxorubicin induction
Number of subjects: 67
Study 31086347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with cyclophosphamide induction
Number of subjects: 67
Study 31086347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with irradiation (3 × 8 Gy) induction
Number of subjects: 67
Study 27904156 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine plus thiazide
Number of subjects: 3001
Study 27904156 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine plus β-blocker
Number of subjects: 3001
Study 27904156 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine plus ARB
Number of subjects: 3001
Study 24942223 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 30
Study 23296817 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy diet
Number of subjects: 36
Study 23296817 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet
Number of subjects: 36
Study 23296817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet + ovine leptin (oLeptin)
Number of subjects: 36
Study 22077236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441
Study 22077236 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441
Study 19048338 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality management regime (tape impregnated with agents providing an occlusive dressing)
Number of subjects: 120
Study 19048338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape and gel treatment (Group 3)
Number of subjects: 120
Study 19048338 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups (various treatments across groups)
Number of subjects: 120
Study 19048338 — intervention group
Group type: COMPARATOR
Intervention: Historical outcomes for hypertrophic scarring (Group 4)
Number of subjects: 120
Study 23298499 — intervention group
Group type: EXPERIMENTAL
Intervention: Variofill (2 ml injections, 2 injections in right knee)
Number of subjects: 20
Study 23298499 — intervention group
Group type: COMPARATOR
Intervention: Synvisc (2 ml injections, 2 injections in left knee)
Number of subjects: 20
Study 15943852 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (group B)
Number of subjects: 320
Study 15943852 — intervention group
Group type: COMPARATOR
Intervention: Histamine(2)-receptor antagonist (famotidine)
Number of subjects: 320
Study 15943852 — intervention group
Group type: COMPARATOR
Intervention: Proton-pump inhibitors
Number of subjects: 320
Study 15943852 — intervention group
Group type: COMPARATOR
Intervention: No eradication (group A)
Number of subjects: 320
Study 12799209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenercept 0.125 mg/kg
Number of subjects: 57
Study 12799209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9872247 — intervention group
Group type: EXPERIMENTAL
Intervention: prtF1-containing strains
Number of subjects: 67
Study 9872247 — intervention group
Group type: COMPARATOR
Intervention: Successful eradication
Number of subjects: 67
Study 9872247 — intervention group
Group type: EXPERIMENTAL
Intervention: Persisting strains
Number of subjects: 67
Study 7699494 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute increment intervals of midazolam (1 mg)
Number of subjects: 26
Study 7699494 — intervention group
Group type: COMPARATOR
Intervention: 3-minute increment intervals of midazolam (1 mg)
Number of subjects: 26
Study 2698569 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg slow-release gallopamil (200 mg/day in two divided doses for 7 days)
Number of subjects: 16
Study 2698569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 269254 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushes with 0.132 mm mean diameter nylon filaments
Number of subjects: 0
Study 269254 — intervention group
Group type: COMPARATOR
Intervention: Brushes with 0.280 mm diameter nylon filaments
Number of subjects: 0
Study 12033699 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP), a seven-session intervention with parents and students together
Number of subjects: 33
Study 12033699 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY), a five-session intervention focusing primarily on parents
Number of subjects: 33
Study 12033699 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 33
Study 29395121 — intervention group
Group type: EXPERIMENTAL
Intervention: VeriStrat Good classification
Number of subjects: 481
Study 29395121 — intervention group
Group type: EXPERIMENTAL
Intervention: VeriStrat Poor classification
Number of subjects: 481
Study 26963941 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload training
Number of subjects: 20
Study 25266425 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month afterschool PA program
Number of subjects: 221
Study 22587425 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of a circular plastic wound protector
Number of subjects: 516
Study 22587425 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominal wound edge protection with surgical dressings
Number of subjects: 516
Study 20535051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 477
Study 20535051 — intervention group
Group type: COMPARATOR
Intervention: Simulated acupuncture treatment
Number of subjects: 477
Study 20535051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment after 1 treatment
Number of subjects: 477
Study 20535051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment after 5 treatments
Number of subjects: 477
Study 18580523 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade locked nailing
Number of subjects: 92
Study 18580523 — intervention group
Group type: COMPARATOR
Intervention: Retrograde locked nailing
Number of subjects: 92
Study 16306832 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive selective nerve root injection (SNI) results
Number of subjects: 101
Study 16306832 — intervention group
Group type: COMPARATOR
Intervention: Negative selective nerve root injection (SNI) results
Number of subjects: 101
Study 16306832 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive magnetic resonance imaging (MRI) results
Number of subjects: 101
Study 16306832 — intervention group
Group type: COMPARATOR
Intervention: Negative magnetic resonance imaging (MRI) results
Number of subjects: 101
Study 16306832 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery consistent with SNI findings
Number of subjects: 101
Study 16306832 — intervention group
Group type: COMPARATOR
Intervention: Surgery inconsistent with SNI findings
Number of subjects: 101
Study 12088919 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.17 mg GH/day (starting dose), titrated by steps of 0.17 mg GH/day every 6-8 weeks, maintenance median GH dose of 0.33 mg/day in males and 0.83 mg/day in females
Number of subjects: 18
Study 12088919 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (17 subjects)
Number of subjects: 18
Study 10206440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoosmolality induced by intravenous administration of desmopressin, liberal ingestion of water, and infusion of hypotonic (0.45%) saline solution
Number of subjects: 7
Study 10206440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoosmolality during hyperinsulinemia and euglycemic clamping
Number of subjects: 7
Study 10206440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoosmolality
Number of subjects: 7
Study 10206440 — intervention group
Group type: COMPARATOR
Intervention: Control (isoosmolar conditions)
Number of subjects: 7
Study 7615114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic GIFT
Number of subjects: 133
Study 7615114 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic GIFT
Number of subjects: 133
Study 2514824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion starting at 2 mU/min up to 16 mU/min during the second stage of labour
Number of subjects: 226
Study 2514824 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during the second stage of labour
Number of subjects: 226
Study 2514824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 226
Study 327432 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 24
Study 327432 — intervention group
Group type: COMPARATOR
Intervention: Progressive relaxation treatment
Number of subjects: 24
Study 31931444 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2) plus cisplatin (80 mg/m2) (arm A)
Number of subjects: 111
Study 31931444 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) plus carboplatin (AUC 6) (arm B)
Number of subjects: 111
Study 31124931 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed proanthocyanidin extract (GSPE) 150 mg/d
Number of subjects: 124
Study 31124931 — intervention group
Group type: COMPARATOR
Intervention: Calcium dobesilate (CD) 750 mg/d
Number of subjects: 124
Study 31124931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 29020962 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia (MUA) followed by an intensive physiotherapy treatment protocol.
Number of subjects: 82
Study 29020962 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone, with advice and education based on guidelines.
Number of subjects: 82
Study 25618535 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia and bilateral nerve stimulator-guided pudendal nerve block (15 mL of Ropivacaïne 5 mg.mL(‐1)+0,5 μg.kg(‐1) of Clonidine)
Number of subjects: 83
Study 25618535 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 83
Study 23714325 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortified yoghurt (FY)
Number of subjects: 1010
Study 23714325 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified yoghurt (NFY)
Number of subjects: 1010
Study 21852579 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline-EDTA lock solution
Number of subjects: 204
Study 21852579 — intervention group
Group type: COMPARATOR
Intervention: Conventional unfractionated heparin
Number of subjects: 204
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (200 mg)
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 2% lidocaine (100 mg + 400 mg)
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (300 mg)
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine with 2% lidocaine (150 mg + 400 mg)
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-lidocaine mixture
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine-lidocaine mixture
Number of subjects: 82
Study 19151302 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 82
Study 19151302 — intervention group
Group type: COMPARATOR
Intervention: long-acting local anesthetic alone
Number of subjects: 82
Study 19151302 — intervention group
Group type: EXPERIMENTAL
Intervention: mixture of long-acting local anesthetic with lidocaine
Number of subjects: 82
Study 17014429 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (3 x 10(9)Lactobacillus acidophilus LAVRI‐A1; Probiomics)
Number of subjects: 178
Study 17014429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin alone)
Number of subjects: 178
Study 12713754 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusive (in-group) prime
Number of subjects: 0
Study 12713754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive (out-group) prime
Number of subjects: 0
Study 12713754 — intervention group
Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 0
Study 10960406 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36
Study 10960406 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study 10960406 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 36
Study 9004851 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for the prevention of allergic diseases (A2 group, n = 15)
Number of subjects: 482
Study 9004851 — intervention group
Group type: COMPARATOR
Intervention: Control group (A1 group, n = 20)
Number of subjects: 482
Study 9004851 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of laboratory tests (group B, n = 66)
Number of subjects: 482
Study 9004851 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of immunoclinical diagnoses (group C, n = 364)
Number of subjects: 482
Study 1456564 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm NO2 exposure for 4 hours with exercise sessions
Number of subjects: 26
Study 1456564 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure for 4 hours with exercise sessions
Number of subjects: 26
Study 1456564 — intervention group
Group type: COMPARATOR
Intervention: Field self-measurements during clean air weeks
Number of subjects: 26
Study 1456564 — intervention group
Group type: COMPARATOR
Intervention: Field self-measurements during NO2 exposure weeks
Number of subjects: 26
Study 1456564 — intervention group
Group type: EXPERIMENTAL
Intervention: Field data
Number of subjects: 26